These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 26966430)
1. Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance. Jang HJ; Hong EM; Jang J; Choi JE; Park SW; Byun HW; Koh DH; Choi MH; Kae SH; Lee J Gastroenterol Res Pract; 2016; 2016():7891374. PubMed ID: 26966430 [TBL] [Abstract][Full Text] [Related]
2. The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells. Ling LU; Lin H; Tan KB; Chiu GN Int J Oncol; 2009 Dec; 35(6):1463-71. PubMed ID: 19885570 [TBL] [Abstract][Full Text] [Related]
3. Simvastatin enhances irinotecan-induced apoptosis in prostate cancer via inhibition of MCL-1. Alqudah MAY; Mansour HT; Mhaidat N Saudi Pharm J; 2018 Feb; 26(2):191-197. PubMed ID: 30166915 [TBL] [Abstract][Full Text] [Related]
4. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines. Mans DR; Grivicich I; Peters GJ; Schwartsmann G Eur J Cancer; 1999 Dec; 35(13):1851-61. PubMed ID: 10674003 [TBL] [Abstract][Full Text] [Related]
5. Butyrate, a dietary fiber derivative that improves irinotecan effect in colon cancer cells. Encarnação JC; Pires AS; Amaral RA; Gonçalves TJ; Laranjo M; Casalta-Lopes JE; Gonçalves AC; Sarmento-Ribeiro AB; Abrantes AM; Botelho MF J Nutr Biochem; 2018 Jun; 56():183-192. PubMed ID: 29587241 [TBL] [Abstract][Full Text] [Related]
6. A new herbal formula BP10A exerted an antitumor effect and enhanced anticancer effect of irinotecan and oxaliplatin in the colon cancer PDTX model. Kim J; Kim HY; Hong S; Shin S; Kim YA; Kim NS; Bang OS Biomed Pharmacother; 2019 Aug; 116():108987. PubMed ID: 31112870 [TBL] [Abstract][Full Text] [Related]
7. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models. Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105 [TBL] [Abstract][Full Text] [Related]
8. Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios. Harasym TO; Tardi PG; Harasym NL; Harvie P; Johnstone SA; Mayer LD Oncol Res; 2007; 16(8):361-74. PubMed ID: 17913044 [TBL] [Abstract][Full Text] [Related]
9. Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment. Tosi D; Pérez-Gracia E; Atis S; Vié N; Combès E; Gabanou M; Larbouret C; Jarlier M; Mollevi C; Torro A; Del Rio M; Martineau P; Gongora C BMC Cancer; 2018 Aug; 18(1):812. PubMed ID: 30103709 [TBL] [Abstract][Full Text] [Related]
10. Simvastatin enhances the chemotherapeutic efficacy of S-1 against bile duct cancer: E2F-1/TS downregulation might be the mechanism. Cai JP; Chen W; Hou X; Liang LJ; Hao XY; Yin XY Anticancer Drugs; 2013 Nov; 24(10):1020-9. PubMed ID: 23941814 [TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumor activity of capecitabine in combination with irinotecan. Cao S; Durrani FA; Rustum YM Clin Colorectal Cancer; 2005 Jan; 4(5):336-43. PubMed ID: 15663838 [TBL] [Abstract][Full Text] [Related]
12. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis. Pencreach E; Guérin E; Nicolet C; Lelong-Rebel I; Voegeli AC; Oudet P; Larsen AK; Gaub MP; Guenot D Clin Cancer Res; 2009 Feb; 15(4):1297-307. PubMed ID: 19190131 [TBL] [Abstract][Full Text] [Related]
13. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618 [TBL] [Abstract][Full Text] [Related]
14. Chemosensitivity of resistant colon cancer cell lines to lobaplatin, heptaplatin, and dicycloplatin. Wei W; Liu Z; Chen X; Bi F Int J Clin Pharmacol Ther; 2014 Aug; 52(8):702-7. PubMed ID: 24986092 [TBL] [Abstract][Full Text] [Related]
15. Synergistic effects of combined treatment with simvastatin and exemestane on MCF-7 human breast cancer cells. Shen Y; Du Y; Zhang Y; Pan Y Mol Med Rep; 2015 Jul; 12(1):456-62. PubMed ID: 25738757 [TBL] [Abstract][Full Text] [Related]
16. Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo. Guichard S; Cussac D; Hennebelle I; Bugat R; Canal P Int J Cancer; 1997 Nov; 73(5):729-34. PubMed ID: 9398054 [TBL] [Abstract][Full Text] [Related]
17. In vitro sensitivity of human endometrial cancer cell lines to paclitaxel or irinotecan (CPT-11) in combination with other aniticancer drugs. Hiramatsu HP; Kikuchi Y; Seto H; Nagata I Anticancer Drugs; 2000 Aug; 11(7):573-8. PubMed ID: 11036961 [TBL] [Abstract][Full Text] [Related]
18. Pre-clinical evaluation of the activity of irinotecan as a basis for regional chemotherapy. Hofmann C; Buttenschoen K; Straeter J; Henne-Bruns D; Kornmann M Anticancer Res; 2005; 25(2A):795-804. PubMed ID: 15868911 [TBL] [Abstract][Full Text] [Related]
19. Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent. Liu J; Chi D; Pan S; Zhao L; Wang X; Wang D; Wang Y Int J Pharm; 2019 Feb; 557():264-272. PubMed ID: 30599233 [TBL] [Abstract][Full Text] [Related]
20. Irinotecan/5-fluorouracil combination induces alterations in mitochondrial membrane potential and caspases on colon cancer cell lines. Grivicich I; Regner A; da Rocha AB; Grass LB; Alves PA; Kayser GB; Schwartsmann G; Henriques JA Oncol Res; 2005; 15(7-8):385-92. PubMed ID: 16491956 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]